



Prothena Corporation plc
 Investor Relations Department
 331 Oyster Point Blvd
 South San Francisco, CA 94080
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: PRTA	
Last Trade:	60.30
Trade Time:	4:00 PM ET Oct 17, 2017
Change:	-0.02 ↓ (-0.033%)
Day Range	59.58 - 61.72
52-Week Range	40.58 - 70.00
Volume	125,541

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Prothena Corporation plc (Nasdaq: PRTA) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies for the potential treatment of diseases that involve amyloid or cell adhesion. Our antibody-based product candidates target a number of potential indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and ATTR amyloidosis (PRX004).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 28, 2017*
[Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis](#)
- Sep 18, 2017*
[Prothena Presents New Research Supporting Clinical Relevance of Å Cardiac Biomarker NT-proBNP in AL Amyloidosis](#)
- Aug 15, 2017*
[Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting](#)
- Aug 8, 2017*
[Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update](#)
- Aug 1, 2017*
[Prothena to Report Second Quarter 2017 Financial Results on August 8](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Feb 27, 2017*
[Annual Report \(10-K\)](#)
- Mar 31, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 9, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2016*
[Quarterly Report \(10-Q\)](#)